Q-omics provides the consensus-scored SNX18P25 profile across patient tissues and cancer cell-line models. SNX18P25 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SNX18P25 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, SNX18P25 RNA expression shows 12,916 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where SNX18P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX18P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX18P25 survival associations across molecular data types. SNX18P25 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX18P25 RNA expression–survival associations across cancer types. High SNX18P25 expression shows unfavorable associations in STAD, LUSC, UCS and LGG, but favorable associations in HNSC and LAML. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for SNX18P25 RNA expression.
This table summarizes SNX18P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNX18P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX18P25 shows higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher SNX18P25 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .001).
This table shows molecular features associated with SNX18P25 in patient tissues and cancer cell lines. In patient samples, SNX18P25 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
